Francois Clavel

Summary

Country: France

Publications

  1. ncbi request reprint AIDS 2002. Virology: overview
    Francois Clavel
    Laboratoire de Recherche Antivirale, IMEA INSERM, Hopital Bichat Claude Bernard, Paris, France
    AIDS 16:S1-2. 2002
  2. ncbi request reprint HIV drug resistance
    Francois Clavel
    Unité de Recherche Antivirale, Institut National de la Sante et de la Recherche Medicale, Unité 552, Hopital Bichat Claude Bernard, Paris
    N Engl J Med 350:1023-35. 2004
  3. pmc Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen
    Aurélie Barrail-Tran
    Assistance Publique Hopitaux de Paris, Hopital Bicetre, Service de Pharmacie Clinique, Paris, France
    Antimicrob Agents Chemother 52:1642-6. 2008
  4. ncbi request reprint Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109)
    Odile Launay
    Faculte de Medecine, Universite Paris Descartes, Service de Medecine Interne, Hopital Cochin, AP HP, Paris, France
    Antivir Ther 11:889-99. 2006
  5. ncbi request reprint Low genetic barrier to large increases in HIV-1 cross-resistance to protease inhibitors during salvage therapy
    Laurence Morand-Joubert
    AP HP, Centre Hospitalo Universitaire Saint Antoine, Paris, France
    Antivir Ther 11:143-54. 2006
  6. ncbi request reprint Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial
    Jean Luc Meynard
    INSERM SC4, Hopital Saint Antoine, Paris, France
    AIDS 16:727-36. 2002
  7. ncbi request reprint Impact of insertions in the HIV-1 p6 PTAPP region on the virological response to amprenavir
    Stephane Lastere
    Laboratoire de Virologie, Hopital Bichat Claude Bernard, Paris, France
    Antivir Ther 9:221-7. 2004
  8. pmc Human immunodeficiency virus type 1 variants isolated from single plasma samples display a wide spectrum of neutralization sensitivity
    Katharina Skrabal
    INSERM U552 Recherche Antivirale, Paris, France
    J Virol 79:11848-57. 2005
  9. pmc Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors
    Charlotte Charpentier
    INSERM U552, Hopital Bichat Claude Bernard, 75018 Paris, France
    J Virol 78:4234-47. 2004
  10. pmc Quantification of the effects on viral DNA synthesis of reverse transcriptase mutations conferring human immunodeficiency virus type 1 resistance to nucleoside analogues
    Francine Bouchonnet
    INSERM U 552, Hopital Bichat Claude Bernard, 46, rue Henri Huchard, 750918 Paris, France
    J Virol 79:812-22. 2005

Collaborators

Detail Information

Publications34

  1. ncbi request reprint AIDS 2002. Virology: overview
    Francois Clavel
    Laboratoire de Recherche Antivirale, IMEA INSERM, Hopital Bichat Claude Bernard, Paris, France
    AIDS 16:S1-2. 2002
  2. ncbi request reprint HIV drug resistance
    Francois Clavel
    Unité de Recherche Antivirale, Institut National de la Sante et de la Recherche Medicale, Unité 552, Hopital Bichat Claude Bernard, Paris
    N Engl J Med 350:1023-35. 2004
  3. pmc Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen
    Aurélie Barrail-Tran
    Assistance Publique Hopitaux de Paris, Hopital Bicetre, Service de Pharmacie Clinique, Paris, France
    Antimicrob Agents Chemother 52:1642-6. 2008
    ..High amprenavir and lopinavir concentrations in these patients might explain why plasma concentrations and the phenotypic IQ have poor predictive value...
  4. ncbi request reprint Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109)
    Odile Launay
    Faculte de Medecine, Universite Paris Descartes, Service de Medecine Interne, Hopital Cochin, AP HP, Paris, France
    Antivir Ther 11:889-99. 2006
    ..We hypothesized that this delay period could be based on a simplified treatment, which would reduce drug toxicity, stabilize resistance, and prevent resurgence of wild-type virus...
  5. ncbi request reprint Low genetic barrier to large increases in HIV-1 cross-resistance to protease inhibitors during salvage therapy
    Laurence Morand-Joubert
    AP HP, Centre Hospitalo Universitaire Saint Antoine, Paris, France
    Antivir Ther 11:143-54. 2006
    ....
  6. ncbi request reprint Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial
    Jean Luc Meynard
    INSERM SC4, Hopital Saint Antoine, Paris, France
    AIDS 16:727-36. 2002
    ..To assess the respective value of phenotype versus genotype versus standard of care for choosing antiretroviral therapy in patients failing protease inhibitor-containing regimens...
  7. ncbi request reprint Impact of insertions in the HIV-1 p6 PTAPP region on the virological response to amprenavir
    Stephane Lastere
    Laboratoire de Virologie, Hopital Bichat Claude Bernard, Paris, France
    Antivir Ther 9:221-7. 2004
    ..In conclusion, these results suggest that insertions in the p6 region of HIV-1 gag gene may affect the VR, in highly pre-treated patients receiving an unboosted APV-containing regimen...
  8. pmc Human immunodeficiency virus type 1 variants isolated from single plasma samples display a wide spectrum of neutralization sensitivity
    Katharina Skrabal
    INSERM U552 Recherche Antivirale, Paris, France
    J Virol 79:11848-57. 2005
    ..The order of sensitivity depended on the serum used and was not associated with virus tropism. The neutralization potency of sera increased with the duration of the infection for both autologous and heterologous neutralization...
  9. pmc Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors
    Charlotte Charpentier
    INSERM U552, Hopital Bichat Claude Bernard, 75018 Paris, France
    J Virol 78:4234-47. 2004
    ....
  10. pmc Quantification of the effects on viral DNA synthesis of reverse transcriptase mutations conferring human immunodeficiency virus type 1 resistance to nucleoside analogues
    Francine Bouchonnet
    INSERM U 552, Hopital Bichat Claude Bernard, 46, rue Henri Huchard, 750918 Paris, France
    J Virol 79:812-22. 2005
    ....
  11. ncbi request reprint Impact of antiretroviral treatment on the tropism of HIV-1 plasma virus populations
    Katharina Skrabal
    INSERM U 552, Recherche Antivirale, Paris, France
    AIDS 17:809-14. 2003
    ..To study the impact of antiretroviral therapy on the tropism of plasma HIV-1 virus populations during treatment response and virological escape...
  12. ncbi request reprint Hypermutation of HIV-1 DNA in the absence of the Vif protein
    Denise Lecossier
    INSERM U552, Paris, France
    Science 300:1112. 2003
  13. ncbi request reprint Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure
    Gilles Raguin
    Service de Maladies Infectieuses, Hopital Saint Antoine, Assistance Publique Hopitaux de Paris, Paris, France
    Antivir Ther 9:615-25. 2004
    ....
  14. ncbi request reprint Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine
    Denise Lecossier
    INSERM U552, Hopital Bichat Claude Bernard, Paris, France
    J Acquir Immune Defic Syndr 38:37-42. 2005
    ..These findings support the idea that minority viral populations with distinct resistance genotypes, although undetectable by standard genotyping, can contribute to the failure of salvage regimens...
  15. pmc Functional diversity of HIV-1 envelope proteins expressed by contemporaneous plasma viruses
    Tamara Nora
    Unité de Recherche Antivirale, INSERM U 552, Universite Denis Diderot Paris 7, Paris F 75018, France
    Retrovirology 5:23. 2008
    ..Less information is available concerning the extent that envelope sequence diversity translates into a diversity of phenotypic properties, including infectivity and resistance to entry inhibitors...
  16. ncbi request reprint Synergistic inhibition of protease-inhibitor-resistant HIV type 1 by saquinavir in combination with atazanavir or lopinavir
    Elisabeth Dam
    VIRALLIANCE, Paris, France
    Antivir Ther 12:371-80. 2007
    ..Evidence of synergistic inhibition of wild-type HIV has been reported for saquinavir with atazanavir or lopinavir...
  17. pmc Functional central polypurine tract provides downstream protection of the human immunodeficiency virus type 1 genome from editing by APOBEC3G and APOBEC3B
    Sebastien Wurtzer
    Unité de Recherche Antivirale, INSERM U552, Paris, France
    J Virol 80:3679-83. 2006
    ..Thus, in addition to other potential functions, the cPPT could help protect lentiviruses from editing by cytidine deaminases of the APOBEC family...
  18. pmc Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors
    Beatrice Labrosse
    INSERM U 552, Recherche Antivirale, Hopital Bichat Claude Bernard, Paris, France
    J Virol 77:1610-3. 2003
    ....
  19. pmc Effect of cell cycle arrest on the activity of nucleoside analogues against human immunodeficiency virus type 1
    Sebastien Wurtzer
    Unité de Recherche Antivirale, INSERM U552, Hopital Bichat Claude Bernard, 46 rue Henri Huchard, 75018 Paris, France
    J Virol 79:14815-21. 2005
    ....
  20. ncbi request reprint In vivo selection by enfuvirtide of HIV type-1 env quasispecies with optimal potential for phenotypic expression of HR1 mutations
    Armelle Goubard
    INSERM U552, Paris, France
    Antivir Ther 14:597-602. 2009
    ....
  21. ncbi request reprint Clinically validated genotype analysis: guiding principles and statistical concerns
    Francoise Brun-Vezinet
    Hospital Bichat Claude Bernard, Paris, France
    Antivir Ther 9:465-78. 2004
    ....
  22. ncbi request reprint Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088)
    Muriel Vray
    INSERM EMI 0214, Universite Pierre et Marie Curie, Paris, France
    Antivir Ther 8:427-34. 2003
    ..To identify predictors of the virological response to antiretroviral therapy in patients in whom initial therapy has failed...
  23. pmc Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss
    Elisabeth Dam
    INSERM U552, Paris, France
    PLoS Pathog 5:e1000345. 2009
    ..Further compensatory mutations render viral RC independent of the A431V or I437V mutations while their effect on resistance persists...
  24. pmc Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients
    Beatrice Labrosse
    INSERM U552, Unité de Recherche Antivirale, Hopital Bichat Claude Bernard, Paris, France
    J Virol 80:8807-19. 2006
    ..Thus, the envelope genetic context appears to play a critical role in the selection of HR1 mutations and the expression of ENF resistance, thereby conditioning the evolution of HIV-1 under fusion inhibitor selective pressure...
  25. ncbi request reprint Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial
    Christophe Piketty
    Department of Immunology, Hôpital Georges Pompidou, Assistance Publique Hopitaux de Paris, Paris, France
    Antivir Ther 11:213-21. 2006
    ..Ritonavir (RTV)-boosted atazanavir (ATV) and tenofovir disoproxil fumarate (TDF-DF) are promising in highly experienced patients because of their pharmacokinetic profile, activity, safety and resistance properties...
  26. pmc Human immunodeficiency virus type 1: resistance to nucleoside analogues and replicative capacity in primary human macrophages
    Danielle Perez-Bercoff
    Antiviral Research Unit, INSERM U552, Hopital Bichat Claude Bernard, 46 rue Henri Huchard, 75018 Paris, France
    J Virol 81:4540-50. 2007
    ....
  27. pmc Contribution of recombination to the evolution of human immunodeficiency viruses expressing resistance to antiretroviral treatment
    Tamara Nora
    INSERM U 552, Universite Paris 7 Denis Diderot, Faculte de Medecine Xavier Bichat, Paris, France
    J Virol 81:7620-8. 2007
    ....
  28. pmc Detection of extensive cross-neutralization between pandemic and seasonal A/H1N1 Influenza Viruses using a pseudotype neutralization assay
    Beatrice Labrosse
    Institut Universitaire d Hematologie, Universite Paris Diderot, Paris, France
    PLoS ONE 5:e11036. 2010
    ..In particular, the extent that previous infection or vaccination by seasonal A/H1N1 viruses can elicit protective immunity against pandemic A/H1N1 is unclear...
  29. pmc HIV resistance to raltegravir
    Francois Clavel
    INSERM U941, Institut Universitaire d Hematologie, Hopital Saint Louis, Paris, France
    Eur J Med Res 14:47-54. 2009
    ....
  30. pmc Enhancement of the influenza A hemagglutinin (HA)-mediated cell-cell fusion and virus entry by the viral neuraminidase (NA)
    Bin Su
    INSERM U941, Génétique et Ecologie des Virus, Institut Universitaire d Hematologie, Hopital Saint Louis, Universite Paris Diderot Paris 7, Paris, France
    PLoS ONE 4:e8495. 2009
    ..In this study we have examined the impact of NA expression on influenza HA-mediated viral membrane fusion and virion infectivity...
  31. pmc Delaying reverse transcription does not increase sensitivity of HIV-1 to human TRIM5α
    Emilie Battivelli
    Institut National de la Santé et de la Recherche Médicale INSERM U941, Paris, France
    PLoS ONE 8:e52434. 2013
    ..It is unknown, however, if increasing the time available for capsid-hTRIM5α interactions would actually render viruses more sensitive to hTRIM5α...
  32. pmc Pressure from TRIM5α Contributes to Control of HIV-1 Replication by Individuals Expressing Protective HLA-B Alleles
    Clémence Granier
    INSERM U941, Paris, France
    J Virol 87:10368-80. 2013
    ....
  33. pmc Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir
    Xavier Duval
    Service des Maladies Infectieuses et Tropicales, Hopital Bichat Claude Bernard, Paris, France
    Antimicrob Agents Chemother 46:570-4. 2002
    ..03 to 0.70) and 7.0 (range, 1.4 to 145), respectively. At week 24, 2 of 8 and 13 of 14 patients in groups A and B, respectively, had <200 HIV RNA copies/ml of plasma, including 4 of 5 patients infected with APV-resistant viruses...
  34. pmc Counteraction of tetherin antiviral activity by two closely related SIVs differing by the presence of a Vpu gene
    Kristina Nikovics
    INSERM U941, Paris, France
    PLoS ONE 7:e35411. 2012
    ..denti and C. neglectus tetherins, resulting in a predominantly perinuclear localization...